A Novel Antimalarial Agent that Inhibits Protein Synthesis in <i>Plasmodium falciparum</i>

P Patricia Bravo (Medical Parasitology and Infection Biology Swiss Tropical and Public Health Institute Kreuzstrasse 2 Allschwil 4123 Switzerland) E Eleonora Diamanti (Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)─Helmholtz Centre for Infection Research (HZI) PharmaScienceHub Campus Building E8.1 66123 Saarbrücken Germany) M Mostafa M. Hamed (Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)─Helmholtz Centre for Infection Research (HZI) PharmaScienceHub Campus Building E8.1 66123 Saarbrücken Germany) L Lorenzo Bizzarri (OmicScouts GmbH Lise‐Meitner‐Straße 30 D‐85354 Freising Germany) N Natalie Wiedemar (Medical Parasitology and Infection Biology Swiss Tropical and Public Health Institute Kreuzstrasse 2 Allschwil 4123 Switzerland) A Armin Passecker N Nicolas M. B. Brancucci A Anna Albisetti (Medical Parasitology and Infection Biology Swiss Tropical and Public Health Institute Kreuzstrasse 2 Allschwil 4123 Switzerland) C Christin Gumpp B Boris Illarionov (Hamburg School of Food Science, Institute of Food Chemistry, University of Hamburg 2 , 20146 Hamburg,) M Markus Fischer M Matthias Witschel (BASF‐SE Carl‐Bosch‐Strasse 38 67056 Ludwigshafen Germany) T Tobias Schehl (BASF‐SE Carl‐Bosch‐Strasse 38 67056 Ludwigshafen Germany) H Hannes Hahne (OmicScouts GmbH Lise‐Meitner‐Straße 30 D‐85354 Freising Germany) P Pascal Mäser M Matthias Rottmann A Anna K. H. Hirsch (Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)─Helmholtz Centre for Infection Research (HZI) PharmaScienceHub Campus Building E8.1 66123 Saarbrücken Germany)

Abstract

Abstract The emergence of drug resistance to nearly all antimalarials following their rollout underscores the need for novel chemotypes with novel modes of action to replenish the antimalarial drug‐development pipeline. We identified a novel class of compounds in the antimalarial armory. Compound 31 , characterized by a 2‐hydroxyphenyl benzamide scaffold, displays potent activity against blood‐stage and mature sexual stages of Plasmodium falciparum and no toxicity in human cells. Resistance selection studies with 31 identified a previously unknown point mutation in the P. falciparum multidrug‐resistance protein 1 ( pfmdr1 ) gene, for which we confirmed causality by CRISPR/Cas9‐based gene editing as the primary mediator of resistance. No cross‐resistance toward first‐line antimalarials was identified in compound 31 ‐resistant parasites. Proteomics studies indicated that the primary mode of action of 31 is through direct binding to cytosolic ribosomal subunits, thereby inhibiting protein synthesis in the parasite. Taken together, compound 31 is a promising starting point for the development of a next‐generation antimalarial.

Article Details

Volume / Issue Vol. 64, Issue 49
Published December 01, 2025
ISSN 1433-7851
Publisher Wiley

Journal Info

Angewandte Chemie International Edition

Wiley

ISSN: 1433-7851 Physical Sciences

Authors (17)

P

Patricia Bravo

Medical Parasitology and Infection Biology Swiss Tropical and Public Health Institute Kreuzstrasse 2 Allschwil 4123 Switzerland

E

Eleonora Diamanti

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)─Helmholtz Centre for Infection Research (HZI) PharmaScienceHub Campus Building E8.1 66123 Saarbrücken Germany

M

Mostafa M. Hamed

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)─Helmholtz Centre for Infection Research (HZI) PharmaScienceHub Campus Building E8.1 66123 Saarbrücken Germany

L

Lorenzo Bizzarri

OmicScouts GmbH Lise‐Meitner‐Straße 30 D‐85354 Freising Germany

N

Natalie Wiedemar

Medical Parasitology and Infection Biology Swiss Tropical and Public Health Institute Kreuzstrasse 2 Allschwil 4123 Switzerland

A

Armin Passecker

N

Nicolas M. B. Brancucci

A

Anna Albisetti

Medical Parasitology and Infection Biology Swiss Tropical and Public Health Institute Kreuzstrasse 2 Allschwil 4123 Switzerland

C

Christin Gumpp

B

Boris Illarionov

Hamburg School of Food Science, Institute of Food Chemistry, University of Hamburg 2 , 20146 Hamburg,

M

Markus Fischer

M

Matthias Witschel

BASF‐SE Carl‐Bosch‐Strasse 38 67056 Ludwigshafen Germany

T

Tobias Schehl

BASF‐SE Carl‐Bosch‐Strasse 38 67056 Ludwigshafen Germany

H

Hannes Hahne

OmicScouts GmbH Lise‐Meitner‐Straße 30 D‐85354 Freising Germany

P

Pascal Mäser

M

Matthias Rottmann

A

Anna K. H. Hirsch

Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)─Helmholtz Centre for Infection Research (HZI) PharmaScienceHub Campus Building E8.1 66123 Saarbrücken Germany